rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers (NCT03865472) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
United States206 participantsStarted 2018-11-10
Plain-language summary
This trial studies best dose and how well repetitive transcranial magnetic stimulation (rTMS) works in promoting smoking cessation and preventing relapse in current smokers. rTMS is a form of brain stimulation therapy that controls nerve cell activity, increases blood flow in the brain, and improves cognitive function.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants will be right-handed
* Negative urine drug screen at the baseline assessment
* Ability to read at the 8th grade level
* Passes the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire (TASS)
* Participants must smoke between 5 and 25 cigarettes per day with the intent to quit smoking in the next 30 days
* Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
* Study 1: Participants will be right-handed and have been diagnosed with primary non-small and small cell lung cancer or with non-skin squamous cell HNC (self-reported)
* Study 1: Age 18+
* Study 1: Negative urine drug screen at the baseline assessment
* Study 1: Ability to read at the 8th grade level
* Study 1: Passes the Transcranial Magnetic Stimulation Adult Safety and Screening Questionnaire (TASS)
* Study 1: Participants must smoke at least 4 cigarettes per day and intend to quit smoking in the next 60 days
* Study 1: Has been diagnosed with primary non-small cell LC or with primary non-skin squamous cell HNC (self-reported)
* Study 2: Participants will be healthy right-handed adults
* Study 2: Age 18-65 years old
* Study 2: Negative urine drug screen at the baseline assessment
* Study 2: Ability to read at the 8th grade level
* Study 2: Passes the Transcranial Magneti…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.